journal article·2020-08Open access

Assessing the targeting and fate of cathepsin k antibody-modified nanoparticles in a rat abdominal aortic aneurysm model

Andrew Camardo, Sarah Carney, Anand Ramamurthi

Acta Biomaterialia· Volume 112

Abstract

Abdominal aortic aneurysms (AAAs), a prototypic proteolytic cardiovascular disorder, are localized expansions of the aortal wall. Chronically upregulated and overexpressed proteases irreversibly degrade and disrupt the elastic matrix, which provides stretch and recoil properties to the aortal wall. Adult vascular smooth muscle cells are inherently unable to produce sufficient elastin to form new elastic fibers to naturally repair the aortal wall and the AAA continues to grow until fatal rupture. Surgical intervention is reserved for AAAs with a high risk of rupture, but there is currently no treatment for small, still growing AAAs. We have previously developed matrix regenerative PEG-PLGA nanoparticles (NPs) with pro-elastogenic and anti-proteolytic properties that act synergistically with a released therapeutic. However, strategies are required to effectively deliver these NPs to the disease site to avail of these benefits. We have identified cathepsin K, a protease overexpressed in AAA tissue, as a potential substrate for antibody based active targeting. We sought to assess the safety and biocompatibility of NPs with anti-cathepsin K antibodies conjugated to the NP surface (cat K Ab-NPs) and then assess their biodistribution and retention in both the targeted aorta and non-target organs in a rat AAA model. In this work, we show that cat K Ab-NPs can selectively target the aneurysmal aorta in a rat AAA model. However, there is unwanted NP uptake and retention in non-target organs that can be addressed in future work. Still, cathepsin K is a viable target for active delivery of NPs in an AAA model. STATEMENT OF SIGNIFICANCE: We have previously developed elastic matrix regenerative polymer nanoparticles (NPs), but require strategies to efficiently target the disease site. Antibodies against cathepsin K, an overexpressed protease in abdominal aortic aneurysms, have been conjugated to the NP surface to act as a targeting moiety. In this work, we assessed NP safety and in vivo biodistribution in an aneurysmal rat model and demonstrated positive targeting and retention for up to 2 weeks within the aortal wall.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Aortic aneurysm repair treatments · Infectious Aortic and Vascular Conditions · Aortic Disease and Treatment Approaches

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (41)

Show source-provided references
1. MMPs–role in cardiovascular development and disease10.2741/1810 ↗
2. Multiple roles of the extracellular matrix in inflammation10.2174/138161209787846685 ↗
3. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease10.1161/CIRCULATIONAHA.105.573865 ↗
4. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease10.1016/j.bcp.2007.07.004 ↗
5. Advances in biomimetic regeneration of elastic matrix structures10.1007/s13346-012-0070-6 ↗
6. Decreased Elastin Synthesis in Normal Development and in Long-term Aortic Organ and Cell Cultures Is Related to Rapid and Selective Destabilization of mRNA for Elastin10.1161/01.RES.77.6.1107 ↗
7. Abdominal aortic aneurysm: A comprehensive review
8. Multifunctional nanoparticles for doxycycline delivery towards localized elastic matrix stabilization and regenerative repair10.1016/j.actbio.2013.01.023 ↗
9. Multifunctional, JNK-inhibiting nanotherapeutics for augmented elastic matrix regenerative repair in aortic aneurysms10.1007/s13346-017-0419-y ↗
10. Nanoparticles in drug delivery: Past, present and future10.1016/j.addr.2012.04.010 ↗
11. The Smart Targeting of Nanoparticles10.2174/13816128113199990375 ↗
12. Active Targeting Strategies Using Biological Ligands for Nanoparticle Drug Delivery Systems
13. Cysteine protease cathepsins in cardiovascular disease: from basic research to clinical trials10.1038/s41569-018-0002-3 ↗
14. Do Cathepsins Play a Role in Abdominal Aortic Aneurysm Pathogenesis?10.1196/annals.1383.028 ↗
15. Cathepsin K-targeted sub-micron particles for regenerative repair of vascular elastic matrix10.1016/j.actbio.2017.01.032 ↗
16. Elastogenic Inductability of Smooth Muscle Cells from a Rat Model of Late Stage Abdominal Aortic Aneurysms10.1089/ten.tea.2010.0526 ↗
17. Immuno-nanotherapeutics to Inhibit Macrophage Polarization for Non-Small-Cell Lung Cancers
18. Analysis of Complement Activation by Nanoparticles
19. Evaluating smooth muscle cells from CaCl2-induced rat aortal expansions as a surrogate culture model for study of elastogenic induction of human aneurysmal cells10.1089/ten.tea.2010.0475 ↗
20. Spatio-Temporal Mapping of Matrix Remodeling and Evidence of in-situ Elastogenesis in Experimental Abdominal Aortic Aneurysms10.1002/term.1905 ↗
21. Basic and clinical biostatistics. Beth Dawson-Saunders and Robert G. Trapp, Appleton and Lange, Connecticut, 1990. ISBN: C-8385-4541-410.1002/sim.4780101016 ↗
22. Quantitative expression and localization of cysteine and aspartic proteases in human abdominal aortic aneurysms10.1038/emm.2014.20 ↗
23. Role of Cathepsin K, L and S in Blood Vessel Remodeling, in: R. Bush (Ed.)10.5772/21311 ↗
24. Elastase-induced experimental aneurysms in rats10.1161/01.CIR.82.3.973 ↗
25. The elastase infusion model of experimental aortic aneurysms: synchrony of induction of endogenous proteinases with matrix destruction and inflammatory cell response10.1016/0741-5214(94)90175-9 ↗
26. Histopathological analysis of cellular localization of cathepsins in abdominal aortic aneurysm wall10.1111/j.1365-2613.2012.00819.x ↗
27. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells, J10.1172/JCI181 ↗
28. Cellular expression of cathepsin proteases in symptomatic and asymptomatic AAA
29. Cathepsin K deficiency reduces elastase perfusion-induced abdominal aortic aneurysms in mice10.1161/ATVBAHA.111.235002 ↗
30. Vitro Methods for Assessing Nanoparticle Toxicity
31. Physical approaches to biomaterial design10.1038/nmat2344 ↗
32. A Targeting Nanotherapy for Abdominal Aortic Aneurysms10.1016/j.jacc.2018.08.2188 ↗
33. Prevention of abdominal aortic aneurysm progression by targeted inhibition of matrix metalloproteinase activity with batimastat-loaded nanoparticles10.1161/CIRCRESAHA.115.307207 ↗
34. State-of-the-art in design rules for drug delivery platforms: Lessons learned from FDA-approved nanomedicines10.1016/j.jconrel.2014.05.036 ↗
35. Active targeting schemes for nanoparticle systems in cancer therapeutics10.1016/j.addr.2008.08.005 ↗
36. Principles of nanoparticle design for overcoming biological barriers to drug delivery10.1038/nbt.3330 ↗
37. Nanoparticle targeting to diseased vasculature for imaging and therapy10.1016/j.nano.2014.02.002 ↗
38. Conjugation of cell-penetrating peptides with poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular drug delivery
39. The Effect of Nanoparticle Polyethylene Glycol Surface Density on Ligand-directed Tumor Targeting Studied in vivo by Dual Modality Imaging10.1021/nn301630n ↗
40. The Slow-Binding Inhibition of Cathepsin K by Its Propeptide10.1006/bbrc.2000.3553 ↗
41. Potency and selectivity of inhibition of cathepsin K, L and S by their respective propeptides: Propeptide inhibition of cathepsins K, L and S10.1046/j.1432-1327.2000.01730.x ↗